TerraPower
CPS 49A nuclear innovation company developing advanced reactor designs and clean energy technologies to address climate change and enable global electrification.
TerraPower holds a landmark regulatory milestone—the first NRC construction permit for a non-light water reactor—and is backed by Bill Gates, DOE cost-share, and strategic investors including NVIDIA's NVentures. However, it remains pre-revenue from its core product, faces substantial first-of-a-kind execution risk on the ~$4B Kemmerer project, and financial visibility is extremely limited. The company is best viewed as a high-conviction, long-duration infrastructure bet rather than a near-term commercial opportunity.
First NRC construction permit for a non-LWR reactor (March 2026), establishing a significant regulatory first-mover advantage over fast-spectrum competitors
Integrated molten salt thermal energy storage differentiates Natrium from competing SMR designs by enabling grid-flexible, dispatchable clean power—directly addressing renewable intermittency
Strong strategic capital access: $650M raised in June 2025 from NVentures (NVIDIA), HD Hyundai, and Bill Gates; ~$2B DOE ARDP cost-share; Bill Gates personally committed ~$1B
Multi-market expansion signals: UK GDA entry notification (April 2025), Utah site exploration, Evergy utility partnership, suggesting pipeline beyond a single demonstration plant
Medical isotopes business (Ac-225 for targeted alpha therapy) provides a nearer-term revenue diversification pathway with high strategic value in precision oncology
Claims of ~50% reduction in safety-related concrete, steel, and labor vs. conventional plants could materially improve nuclear construction economics if validated at Kemmerer
First-of-a-kind nuclear projects have a global track record of severe cost and schedule overruns; the ~$4B Kemmerer project has not yet demonstrated construction execution
Pre-revenue from electricity generation with no operating plant; third-party revenue estimates are contradictory ($11M vs. $1-10B from the same source), indicating extreme financial opacity
Sodium-cooled fast reactor supply chain is immature—specialized components, sodium handling, and fast-spectrum materials require vendor development with limited commercial precedent
Regulatory risk extends well beyond the construction permit: operating license, fuel loading, startup testing, and ongoing compliance represent years of additional regulatory milestones
Public acceptance risk for non-LWR nuclear technology remains a factor, particularly for sodium coolant (historically associated with safety incidents at other facilities globally)
The earlier TWR program was abandoned due to geopolitical constraints on China technology transfer, demonstrating vulnerability to policy shifts that could affect future international expansion
Kemmerer Unit 1 cost and schedule overruns could erode investor confidence and delay the entire Natrium commercialization timeline
Sodium supply chain and fast-spectrum component manufacturing lack commercial-scale precedent, creating procurement and quality risks
Operating license approval, fuel qualification, and startup testing represent multi-year regulatory hurdles beyond the construction permit
DOE ARDP cost-share (~$2B) could be subject to political or budgetary changes under future administrations
Medical isotopes business remains early-stage with unverified commercial volumes; revenue materiality is uncertain
Conflicting third-party financial data and private company opacity make independent financial diligence extremely difficult
Kemmerer Unit 1 construction milestones and adherence to budget/schedule targets over 2026-2028
UK Generic Design Assessment progress for Natrium, potentially opening a major international market
Additional utility partnerships or site announcements beyond Wyoming (Utah, Evergy/Kansas) signaling commercial pipeline
MCRE test reactor progress at Idaho National Laboratory validating the molten chloride fast reactor pathway
Medical isotope supply agreements reaching commercial-scale delivery, providing nearer-term revenue validation